<DOC>
	<DOC>NCT02151734</DOC>
	<brief_summary>This is a multi-center, double-dummy, double-blind, randomized, active-controlled, parallel group phase 3 clinical trial to evaluate the efficacy and safety of KALOMIN™ Tab. in patients with acute bronchitis. The aim of this clinical trial is to demonstrate that KALOMIN™ Tab. is clinically non-inferior to Umckamin syrup, as assessed by BSS(Bronchitis Severity Score), in the treatment of acute bronchitis after 7 days.</brief_summary>
	<brief_title>Safety and Efficacy of KALOMIN™ Tab. in Patients With Acute Bronchitis</brief_title>
	<detailed_description />
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<criteria>Male or female patients aged 1275 years old A total score of BSS ≥ 5 The duration of symptoms had to be less than 14 days and no chronic pulmonary disease Patients who voluntarily sign a written informed consent to participate in the trial Indication for antibiotic treatment(e.g. severe respiratory infection) Allergic bronchial asthma Tendency to bleed Severe heart, renal, or liver diseases or decline of immune function Chronic obstructive pulmonary disease Known or supposed hypersensitivity to investigational medication Treatment with antibiotics during the past 4 weeks prior to inclusion in the trial Women during pregnancy or lactation period Clinically significant abnormal values in the screening test(more than twice the upper limit of normal range for ALT, AST, BUN, and Serum Creatinine) Participation in any other trial within 30 days prior to inclusion in the trial Unsuitable patients for enrollment in the opinion of the investigator</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>